Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VIGL | US
0.04
1.16%
Healthcare
Biotechnology
30/06/2024
30/08/2024
3.48
3.51
3.54
3.25
Vigil Neuroscience Inc. a clinical-stage biotechnology company focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia the sentinel immune cells of the brain. Its lead candidate is VGL101 a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) a rare and fatal neurodegenerative disease. The company is also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction with an initial focus on Alzheimer's disease in genetically defined subpopulations. Vigil Neuroscience Inc. was incorporated in 2020 and is headquartered in Watertown Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
37.6%1 month
89.3%3 months
130.2%6 months
119.0%-
-
1.62
0.16
0.12
-3.16
-
-
-89.62M
137.97M
137.97M
-
-
-
-
-70.12
3.79
6.34
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.67
Range1M
1.50
Range3M
3.59
Rel. volume
0.37
Price X volume
184.29K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Achieve Life Sciences Inc | ACHV | Biotechnology | 4.39 | 150.76M | -0.90% | n/a | 41.73% |
Century Therapeutics Inc. Common Stock | IPSC | Biotechnology | 1.76 | 149.10M | 1.73% | n/a | 25.38% |
Capricor Therapeutics Inc | CAPR | Biotechnology | 4.57 | 148.70M | -2.77% | n/a | 45.32% |
Adverum Biotechnologies Inc | ADVM | Biotechnology | 6.94 | 144.36M | 0.87% | n/a | 43.97% |
LogicBio Therapeutics Inc | LOGC | Biotechnology | 5.4 | 141.88M | -0.55% | n/a | 0.00% |
Medicenna Therapeutics Corp | MDNAF | Biotechnology | 1.85 | 141.40M | 17.83% | n/a | 0.00% |
QSI | QSI | Biotechnology | 0.9468 | 134.79M | -2.44% | n/a | 0.71% |
Kodiak Sciences Inc | KOD | Biotechnology | 2.51 | 132.06M | 1.21% | n/a | 81.94% |
INmune Bio Inc | INMB | Biotechnology | 6.62 | 130.96M | -3.50% | n/a | 14.65% |
Nuvectis Pharma Inc. | NVCT | Biotechnology | 6.96 | 129.82M | 2.50% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Saga Communications Inc | SGA | Broadcasting - Radio | 14.72 | 92.17M | -2.06% | 14.72 | 7.10% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.38 | 76.89M | 5.34% | n/a | 268.43% |
Emmis Communications Corporation | EMMS | Broadcasting - Radio | 4.7 | 57.98M | -1.05% | n/a | 54.59% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.16 | 0.97 | Cheaper |
Ent. to Revenue | - | 3,681.29 | - |
PE Ratio | - | 39.83 | - |
Price to Book | 1.62 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 130.20 | 76.13 | Riskier |
Debt to Equity | 0.16 | -2.05 | Expensive |
Debt to Assets | 0.12 | 0.25 | Cheaper |
Market Cap | 137.97M | 4.04B | Emerging |